• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    GW Pharmaceuticals Shareholders Approve Acquisition by Jazz Pharmaceuticals

    4/23/21 4:01:00 PM ET
    $JAZZ
    $GWPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals
    Health Care
    Get the next $JAZZ alert in real time by email

    LONDON and DUBLIN, April 23, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH) (GW) and Jazz Pharmaceuticals plc (NASDAQ:JAZZ) (Jazz) today announced that GW's shareholders voted to approve the acquisition of GW by a subsidiary of Jazz (or its nominee(s)) at the GW shareholder meetings held today. The proposals required to be approved by GW's shareholders in order to complete the acquisition were each approved. In addition, the non-binding, advisory proposal to approve certain compensation arrangements for GW's named executive officers was approved. Detailed information regarding the results will be made available by GW in a filing with the U.S. Securities and Exchange Commission (SEC).

    All shareholder and regulatory approvals required for the acquisition have now been obtained. Completion of the acquisition remains subject to the sanction by the High Court of Justice of England and Wales (Court) and other customary closing conditions. The Court hearing to sanction the acquisition is currently scheduled for May 5, 2021, and the completion of the acquisition is expected to occur shortly thereafter.



    About GW Pharmaceuticals plc

    Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, EPIDIOLEX® (cannabidiol) oral solution, is commercialized in the U.S. by its U.S. subsidiary Greenwich Biosciences for the treatment of seizures associated with Lennox Gastaut syndrome (LGS), Dravet syndrome, or tuberous sclerosis complex (TSC) in patients one year of age and older. This product has received approval in the European Union under the tradename EPIDYOLEX® for the adjunctive treatment of seizures associated with LGS or Dravet syndrome in conjunction with clobazam in patients two years and older and for adjunctive use to treat seizures associated with TSC, in patients two years of age and older. The Company has a deep pipeline of additional cannabinoid product candidates, in particular nabiximols, for which the Company is advancing multiple late-stage clinical programs in order to seek FDA approval in the treatment of spasticity associated with multiple sclerosis and spinal cord injury. The Company has additional cannabinoid product candidates in clinical trials for autism and schizophrenia.

    About Jazz Pharmaceuticals plc

    Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a global biopharmaceutical company dedicated to developing and commercializing life-changing medicines that transform the lives of patients with serious diseases — often with limited or no options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in key therapeutic areas. Our focus is in neuroscience, including sleep and movement disorders, and in oncology, including hematologic malignancies and solid tumors. We actively explore new options for patients including novel compounds, small molecule advancements, biologics and innovative delivery technologies. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in more than 90 countries. For more information, please visit www.jazzpharmaceuticals.com.

    GW Pharmaceuticals Media Contacts:

    US: Kristen Cardillo, Vice President, Corporate Communication

    [email protected] +1 760 579 6628

    UK: Ben Atwell, FTI Consulting

    London [email protected] +44 (0)20 3727 1000

    GW Pharmaceuticals Investor Contact:

    Scott Giacobello, Chief Financial Officer

    [email protected] +1 (760) 795 2200

    Jazz Pharmaceuticals Media Contact:

    Jacqueline Kirby, Vice President, Corporate Affairs & Government Relations

    Ireland +353 1 697 2141

    U.S. +1 215 867 4910

    Jazz Pharmaceuticals Investor Contact:

    Andrea N. Flynn, Ph.D., Vice President, Head, Investor Relations

    Ireland +353 1 634 7887

    U.S. +1 650 496 2717

    Forward Looking Statements

    This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding GW and Jazz including, but not limited to, statements related to the proposed acquisition of GW and the anticipated timing for the completion thereof; statements regarding the expectations and beliefs of the board of directors of GW, GW management, the board of directors of Jazz or Jazz management and other statements that are not historical facts. You can generally identify forward-looking statements by the use of forward-looking terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "explore," "evaluate," "intend," "may," "might," "plan," "potential," "predict," "project," "seek," "should," or "will," or the negative thereof or other variations thereon or comparable terminology. These forward-looking statements are based on each of the companies' current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties, many of which are beyond GW's or Jazz's control. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with GW's and Jazz's ability to complete the acquisition on the proposed terms or on the anticipated timeline, or at all, including: risks and uncertainties related to the sanction of the Court and satisfaction of other closing conditions to consummate the acquisition; the occurrence of any event, change or other circumstance that could give rise to the termination of the definitive transaction agreement relating to the acquisition; risks related to diverting the attention of GW and Jazz management from ongoing business operations; failure to realize the expected benefits of the acquisition; significant transaction costs and/or unknown or inestimable liabilities; the risk of shareholder litigation in connection with the acquisition, including resulting expense or delay; the risk that GW's business will not be integrated successfully or that such integration may be more difficult, time-consuming or costly than expected; Jazz's ability to obtain the expected financing to consummate the acquisition; risks related to future opportunities and plans for the combined company, including the uncertainty of expected future regulatory filings, financial performance and results of the combined company following completion of the acquisition; GW's or the combined company's dependence on the successful commercialization of Epidiolex or Epidyolex (the trade name for Epidiolex in Europe) and the uncertain market potential of Epidiolex/Epidyolex; pharmaceutical product development and the uncertainty of clinical success; the regulatory approval process, including the risks that GW or Jazz may be unable to submit anticipated regulatory filings on the timeframe anticipated, or at all, or that GW or the combined company may be unable to obtain regulatory approvals of any product candidates, including nabiximols and Epidiolex/Epidyolex for additional indications, in a timely manner or at all; disruption from the acquisition, making it more difficult to conduct business as usual or maintain relationships with customers, employees, distributors, suppliers or other third parties; effects relating to the announcement of the acquisition or any further announcements or the consummation of the acquisition on the market price of Jazz ordinary shares, GW American depositary shares or GW ordinary shares; the possibility that, if Jazz does not achieve the perceived benefits of the acquisition as rapidly or to the extent anticipated by financial analysts or investors, the market price of Jazz ordinary shares could decline; regulatory initiatives and changes in tax laws; market volatility; and other risks and uncertainties affecting GW and Jazz, including those described from time to time under the caption "Risk Factors" and elsewhere in GW's and Jazz's SEC filings and reports, including GW's Annual Report on Form 10-K for the fiscal year ended December 31, 2020, Jazz's Annual Report on Form 10-K for the fiscal year ended December 31, 2020, GW's definitive proxy statement filed with the SEC on March 15, 2021 and future filings and reports by either company. In addition, while GW and Jazz expect the COVID-19 pandemic to continue to adversely affect their respective business operations and financial results, the extent of the impact on the combined company's ability to generate sales of and revenues from its approved products, execute on new product launches, its clinical development and regulatory efforts, its corporate development objectives and the value of and market for its ordinary shares, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time. Moreover, other risks and uncertainties of which GW or Jazz are not currently aware may also affect each of the companies' forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. Readers of this announcement are cautioned that forward-looking statements are not guarantees of future performance. The forward-looking statements made in this announcement are made only as of the date hereof or as of the dates indicated in the forward-looking statements and reflect the views stated therein with respect to future events as at such dates, even if they are subsequently made available by GW or Jazz on their respective websites or otherwise. Except as otherwise required by law, neither GW nor Jazz undertakes any obligation, and each expressly disclaims any obligation, to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.



    Primary Logo

    Get the next $JAZZ alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $JAZZ
    $GWPH

    CompanyDatePrice TargetRatingAnalyst
    Jazz Pharmaceuticals plc
    $JAZZ
    3/7/2025$145.00 → $179.00Neutral → Buy
    UBS
    Jazz Pharmaceuticals plc
    $JAZZ
    2/26/2025Overweight → Neutral
    Cantor Fitzgerald
    Jazz Pharmaceuticals plc
    $JAZZ
    2/13/2025$130.00 → $170.00Equal Weight → Overweight
    Wells Fargo
    Jazz Pharmaceuticals plc
    $JAZZ
    12/12/2024$140.00 → $175.00Equal-Weight → Overweight
    Morgan Stanley
    Jazz Pharmaceuticals plc
    $JAZZ
    6/5/2024$169.00Buy
    Goldman
    Jazz Pharmaceuticals plc
    $JAZZ
    1/3/2024$160.00Outperform
    Robert W. Baird
    Jazz Pharmaceuticals plc
    $JAZZ
    11/27/2023$170.00 → $135.00Buy → Neutral
    UBS
    Jazz Pharmaceuticals plc
    $JAZZ
    9/29/2023Mkt Perform
    Raymond James
    More analyst ratings

    $JAZZ
    $GWPH
    SEC Filings

    See more
    • SEC Form 144 filed by Jazz Pharmaceuticals plc

      144 - Jazz Pharmaceuticals plc (0001232524) (Subject)

      7/1/25 4:15:49 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Jazz Pharmaceuticals plc

      DEFA14A - Jazz Pharmaceuticals plc (0001232524) (Filer)

      6/6/25 4:09:11 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Jazz Pharmaceuticals plc

      DEF 14A - Jazz Pharmaceuticals plc (0001232524) (Filer)

      6/6/25 4:06:54 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JAZZ
    $GWPH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • August 12, 2021 - FDA Grants First of its Kind Indication for Chronic Sleep Disorder Treatment

      For Immediate Release: August 12, 2021 The U.S. Food and Drug Administration today approved a new indication for Xywav for idiopathic hypersomnia (IH) in adults. IH is an uncommon chronic sleep disorder that causes people to be excessively sleepy during the day even after a good night's sleep. Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution is already approved for the treatment of catapl

      8/12/21 4:25:43 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JAZZ
    $GWPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chairman & CEO Cozadd Bruce C sold $107,630 worth of Ordinary Shares (1,000 units at $107.63), decreasing direct ownership by 0.23% to 436,973 units (SEC Form 4)

      4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)

      7/3/25 2:56:04 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chairman & CEO Cozadd Bruce C sold $108,950 worth of Ordinary Shares (1,000 units at $108.95), decreasing direct ownership by 0.23% to 437,973 units (SEC Form 4)

      4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)

      6/4/25 4:50:28 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mulligan Seamus bought $9,993,082 worth of Ordinary Shares (101,621 units at $98.34) (SEC Form 4)

      4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)

      5/13/25 6:51:34 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JAZZ
    $GWPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jazz Pharma upgraded by UBS with a new price target

      UBS upgraded Jazz Pharma from Neutral to Buy and set a new price target of $179.00 from $145.00 previously

      3/7/25 8:10:15 AM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jazz Pharma downgraded by Cantor Fitzgerald

      Cantor Fitzgerald downgraded Jazz Pharma from Overweight to Neutral

      2/26/25 1:51:25 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jazz Pharma upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded Jazz Pharma from Equal Weight to Overweight and set a new price target of $170.00 from $130.00 previously

      2/13/25 8:08:59 AM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JAZZ
    $GWPH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mulligan Seamus bought $9,993,082 worth of Ordinary Shares (101,621 units at $98.34) (SEC Form 4)

      4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)

      5/13/25 6:51:34 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Johnson Philip L was granted 15,932 units of Ordinary Shares and bought $1,435,800 worth of Ordinary Shares (12,000 units at $119.65) (SEC Form 4)

      4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)

      3/5/24 7:28:40 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JAZZ
    $GWPH
    Leadership Updates

    Live Leadership Updates

    See more
    • Jazz Pharmaceuticals Announces CEO Succession Plan

      Bruce Cozadd, Co-Founder, Chairperson and CEO, Plans to Retire as CEO Upon Appointment of Successor by the End of 2025; Will Continue as Chair of the Board Mr. Cozadd Has Led Growth of Company from Founding to $4 Billion+ in 2024 Expected Total Revenue Board Will Lead Comprehensive Internal and External Search for New CEO; Intended to be Completed in 2025 DUBLIN, Dec. 16, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that Bruce Cozadd, Co-Founder, Chairperson and Chief Executive Officer (CEO), has informed the Board of Directors of his intent to retire from his role as CEO upon appointment of the Company's next leader, expected by the end of 2025. The Board wil

      12/16/24 4:05:00 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel

      Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, Actelion Pharmaceuticals, Eisai, GSK, and the U.S. FDASOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that Douglas B. Snyder, joined the company as its Senior Vice President, General Counsel on September 18, 2024. "Doug brings a broad legal background in the healthcare field spanning biotechnology, pharm

      9/18/24 6:00:00 AM ET
      $IDYA
      $GWPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Jazz Pharmaceuticals Shareholders Elect Laura Hamill to the Company's Board of Directors at Annual General Meeting

      Ms. Hamill brings extensive experience and proven leadership focused on commercial growth and shareholder value DUBLIN, July 25, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced the election of a new independent director, Laura Hamill, to its Board of Directors. Ms. Hamill, a 35-year veteran of the pharmaceutical industry brings broad executive leadership and global commercial operations expertise to the company's Board. Ms. Hamill's election follows the appointment of Patrick Kennedy earlier this year and reflects Jazz's continued focus on Board renewal. At the Annual General meeting held today, shareholders not only elected Ms. Hamill and Mr. Kennedy but also re-

      7/25/24 4:05:00 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JAZZ
    $GWPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer

      Target Action (PDUFA) Date set for October 7, 2025 Application based on data from IMforte, the first Phase 3 trial demonstrating statistically significant and clinically meaningful improvements in both progression-free and overall survival in the ES-SCLC first-line maintenance setting Jazz to host investor webcast on Tuesday, June 10 at 4:30 p.m. EDT / 9:30 p.m. IST to review Zepzelca data For U.S. media and investors only DUBLIN, June 10, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for Zepzelca® (lurbinectedin) in combination with atezolizumab (Tecentriq®) as

      6/10/25 7:05:00 AM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025

      First presentation of the Phase 4 XYLO switch study reports blood pressure reductions in patients with narcolepsy when switching from twice-nightly high- to low-sodium oxybate Novel intermediate analysis from the DUET trial cohort of patients taking >9 grams evaluated safety and changes in daytime sleepiness in adults with narcolepsy taking Xywav dosages of 9-12 grams per night  For U.S. media and investors only DUBLIN, June 9, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced late-breaking Phase 4 data evaluating treatment benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution in people with narcolepsy. These results are two of Jazz'

      6/9/25 6:00:00 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

      First-line maintenance combination therapy reduced the risk of disease progression or death by 46%, with a median overall survival of 13.2 months vs 10.6 months for atezolizumab alone from the point of randomization First Phase 3 study to demonstrate statistically significant and clinically meaningful improvements in both progression-free and overall survival in ES-SCLC first-line maintenance Results presented at the ASCO 2025 Annual Meeting and simultaneously published in The Lancet Jazz to host investor webcast on Tuesday, June 10 to review Zepzelca data For U.S. media and investors only DUBLIN, June 2, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced positive re

      6/2/25 4:05:00 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JAZZ
    $GWPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Jazz Pharmaceuticals plc (Amendment)

      SC 13G/A - Jazz Pharmaceuticals plc (0001232524) (Subject)

      2/13/24 5:07:58 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Jazz Pharmaceuticals plc (Amendment)

      SC 13G/A - Jazz Pharmaceuticals plc (0001232524) (Subject)

      9/11/23 1:33:44 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Jazz Pharmaceuticals plc (Amendment)

      SC 13G/A - Jazz Pharmaceuticals plc (0001232524) (Subject)

      2/9/23 11:25:15 AM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JAZZ
    $GWPH
    Financials

    Live finance-specific insights

    See more
    • Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025

      DUBLIN, April 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that it will report its 2025 first quarter financial results on Tuesday, May 6, 2025, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss 2025 first quarter financial results and provide a business and financial update.   Audio webcast/conference call:U.S. Dial-In Number: +1 800 715 9871Ireland Dial-In Number: +353 1800 943 926Additional global dial-in numbers are available here.Passcode: 5080203 Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at

      4/22/25 4:15:00 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jazz Pharmaceuticals Completes Acquisition of Chimerix

      - Addition of dordaviprone strengthens Jazz's late-stage oncology pipeline and reinforces commitment to addressing rare diseases with significant unmet need - DUBLIN, April 21, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ("Jazz" or the "Company") today announced the successful completion of its acquisition of Chimerix, Inc. ("Chimerix") for approximately $935 million in cash. Chimerix is now a wholly owned subsidiary of Jazz. "Bringing Chimerix into Jazz adds a novel medicine to our oncology portfolio and advances our efforts to address unmet patient needs," said Bruce Cozadd, chairman and chief executive officer of Jazz. "Dordaviprone has the potential to become the first an

      4/21/25 4:05:00 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance

      – Record total revenues of $4.1 billion in 2024 and $1.1 billion in 4Q24 –– Xywav® and Epidiolex® revenues grew 16% and 15% year-over-year, respectively, in 2024 –– Oncology revenues grew 9% year-over-year in 2024, surpassed $1.1 billion –– Ziihera® approved in 2L HER2+ (IHC3+) BTC; first sales achieved in December 2024 –– 2025 guidance reflects continued top- and bottom-line growth – DUBLIN, Feb. 25, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced financial results for the full year and fourth quarter of 2024 and provided guidance for 2025. "2024 was another strong year as our proven team delivered significant top- and bottom-line growth along with record total r

      2/25/25 4:05:00 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care